{"disease":{"id":"pemphigus","name":"Pemphigus","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":19,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"Pemphigus vulgaris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"rituxan","indication_name":"Pemphigus foliaceus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"orthocaine","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"orthocaine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminobenzoic-acid","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aminobenzoate Potassium","generic_name":"aminobenzoic acid","company_name":"","drug_phase":"unknown","molecular_target":"Carbonic anhydrase 2","drug_class":"Vitamin B Complex Member","quality_score":null,"revenue":null,"mechanism":"Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells."},{"drug_id":"benzoic-acid","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"azathioprine","indication_name":"Pemphigus vulgaris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone-acetate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depo-Medrol","generic_name":"METHYLPREDNISOLONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Depo-Medrol works by binding to the glucocorticoid receptor, which then regulates the expression of genes involved in inflammation and immune response."},{"drug_id":"ruxience","indication_name":"Pemphigus foliaceus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"ruxience","indication_name":"Pemphigus vulgaris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Pemphigus foliaceus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"rituximab","indication_name":"Pemphigus vulgaris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe pemphigus vulgaris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe pemphigus vulgaris in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolon","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Pemphigus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05954416","title":"FARD (RaDiCo Cohort) (RaDiCo-FARD)","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT07457944","title":"Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients","phase":"","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05000216","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04598451","title":"A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04598477","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":183,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04023149","title":"Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT02383589","title":"A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05898308","title":"Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":133,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT06454357","title":"A Clinical Study of B007 in the Treatment of Pemphigus.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT03762265","title":"A Study of PRN1008 in Patients With Pemphigus","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":131,"lead_sponsor_name":"Principia Biopharma, a Sanofi Company","has_results":true},{"nct_id":"NCT05284929","title":"Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Sechenov University","has_results":false},{"nct_id":"NCT06663943","title":"A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Chao Ji","has_results":false},{"nct_id":"NCT06167408","title":"Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06949241","title":"A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06846255","title":"Comparing DCP and DAP for Pemphigus Vulgaris","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Jinnah Postgraduate Medical Centre","has_results":false},{"nct_id":"NCT06863454","title":"Trichoscopy as a Monitoring Tool for Activity and Remission in Pemphigus Vulgaris: A Clinical Study Supported by Immunological Evaluation.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05992727","title":"Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05303272","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05338112","title":"Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Istanbul Medeniyet University","has_results":false},{"nct_id":"NCT02237313","title":"Identification of Vulnerability Factors in the Course of Pemphigus Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT06901427","title":"Impact of a Lifestyle Program on Quality of Life in Pemphigus Patients","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT02704429","title":"A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Principia Biopharma, a Sanofi Company","has_results":true},{"nct_id":"NCT04096222","title":"Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","has_results":false},{"nct_id":"NCT05534776","title":"Validation of 5-Point Investigator Global Assessments for Pemphigus","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Premier Specialists, Australia","has_results":false},{"nct_id":"NCT06654817","title":"Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Chao Ji","has_results":false},{"nct_id":"NCT01920477","title":"Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03334058","title":"A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT06696716","title":"ONO-4059 Study in Patients With Steroid-resistant Pemphigus","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05594472","title":"Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04540133","title":"Dexamethasone Solution and Dexamethasone in Mucolox™","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT06971172","title":"Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04400994","title":"IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06904040","title":"A Single-center Study of CM313 in Patients With Pemphigus","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT07461103","title":"Effect of Topical Insulin on Healing Rate of Pemphigus Lesions","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Alexandria University","has_results":false},{"nct_id":"NCT07384221","title":"Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients","phase":"","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Saglik Bilimleri Universitesi","has_results":false},{"nct_id":"NCT07428915","title":"Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AI Labs Group S.L","has_results":false},{"nct_id":"NCT01559155","title":"Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid","phase":"","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT01930175","title":"Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03075904","title":"A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03239470","title":"Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02613910","title":"Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}